Does TROP2 expression influence clinical decision-making for TNBC currently?
Given TROP2 IHC data exist as an exploratory biomarker in both ASCENT and TB-02 trials.
Community PollStarted
Does TROP2 expression currently influence your treatment decisions in mTNBC?
100 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Emory University School of Medicine
Answered on
At this time, TROP2 IHC expression does not guide treatment selection for TROP2-directed ADCs in TNBC clinical practice. Exploratory biomarker analyses from ASCENT and TROPiCS-02 demonstrated that benefit from sacituzumab govitecan was observed across a range of TROP2 expression levels, without a cl...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
Answered on
A key barrier to clinical adoption of TROP2 testing is the lack of a standardized IHC assay. A study comparing three commonly used TROP2 antibodies (ENZO, Abcam SP295, and Santa Cruz B9) demonstrated only fair-to-moderate inter-assay concordance (AC2 = 0.35), with substantial variability in the prop...
Join for free or sign in to see the full answer